Crescent Biopharma
CBIO
34 hedge funds and large institutions have $14.3M invested in Crescent Biopharma in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 5 closing their positions.
0.01% less ownership
Funds ownership: 0.51% → 0.49% (-0.01%)
3% less funds holding
Funds holding: 35 → 34 (-1)
10% less capital invested
Capital invested by funds: $15.8M → $14.3M (-$1.51M)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$23.4K |
| 2 |
IP
Intellectus Partners
San Francisco,
California
|
+$23.4K |
| 3 |
Man Group
London,
United Kingdom
|
+$12.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$12.4K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.62K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$148K |
| 2 |
Two Sigma Advisers
New York
|
-$79.4K |
| 3 |
Two Sigma Investments
New York
|
-$67.6K |
| 4 |
Millennium Management
New York
|
-$49.2K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$37K |
CBIO Hedge Fund Activity: Q3 2022 in Review
34 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q3 2022, worth a combined $14.3M — down 9.5% from $15.8M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CBIO and 4 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 4 added.
The largest buyer was Vanguard Group, adding an estimated $23.4K. The largest seller was D.E. Shaw & Co, cutting an estimated $148K.
- 34 institutional investors held Crescent Biopharma (CBIO) as of Q3 2022, down from 35 in Q2 2022.
- Funds reported $14.3M of Crescent Biopharma stock for Q3 2022, down 9.5% quarter-over-quarter.
- 4 funds opened new Crescent Biopharma positions in Q3 2022 and 5 closed out, a net change of -1 holder.
- The largest Crescent Biopharma buyer in Q3 2022 was Vanguard Group, an estimated $23.4K added.
- The largest Crescent Biopharma seller in Q3 2022 was D.E. Shaw & Co, an estimated $148K sold.
Based on aggregated 13F filings for Q3 2022.